Tiropramide

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584354

CAS#: 55837-29-1

Description: Tiropramide is an antispasmodic drug useful to inhibit the contractile response of the urinary bladder, as this organ is mainly innervated by noncholinergic excitatory neurons, and in managing abdominal pain in IBS.

Chemical Structure

img
Tiropramide
CAS# 55837-29-1
Instruction

Theoretical Analysis

MedKoo Cat#: 584354
Name: Tiropramide
CAS#: 55837-29-1
Chemical Formula: C28H41N3O3
Exact Mass: 467.31
Molecular Weight: 467.654
Elemental Analysis: C, 71.91; H, 8.84; N, 8.99; O, 10.26

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Tiropramide; CR-605

IUPAC/Chemical Name: Benzenepropanamide, alpha-(benzoylamino)-4-(2-(diethylamino)ethoxy)-N,N-dipropyl-, (+-)-

InChi Key: FDBWMYOFXWMGEY-UHFFFAOYSA-N

InChi Code: InChI=1S/C28H41N3O3/c1-5-18-31(19-6-2)28(33)26(29-27(32)24-12-10-9-11-13-24)22-23-14-16-25(17-15-23)34-21-20-30(7-3)8-4/h9-17,26H,5-8,18-22H2,1-4H3,(H,29,32)

SMILES Code: O=C(N(CCC)CCC)C(NC(C1=CC=CC=C1)=O)CC2=CC=C(OCCN(CC)CC)C=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 467.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Baek SK, Lee SS, Park EJ, Sohn DH, Lee HS. Semi-micro high-performance liquid chromatographic analysis of tiropramide in human plasma using column-switching. J Pharm Biomed Anal. 2003 Feb 5;31(1):185-9. PubMed PMID: 12560063.

2: Kwon OS, Park YJ, Ryu JC, Chung YB. Quantitative analysis of tiropramide in human blood by gas chromatography with nitrogen-phosphorus detector. Arch Pharm Res. 2003 May;26(5):416-20. PubMed PMID: 12785739.

3: Lee KN, Lee OY, Choi MG, Sohn CI, Huh KC, Park KS, Kwon JG, Kim N, Rhee PL, Myung SJ, Lee JS, Lee KJ, Park H, Lee YC, Choi SC, Jung HK, Jee SR, Choi CH, Kim GH, Park MI, Sung IK. Efficacy and Safety of Tiropramide in the Treatment of Patients With Irritable Bowel Syndrome: A Multicenter, Randomized, Double-blind, Non-inferiority Trial, Compared With Octylonium. J Neurogastroenterol Motil. 2014 Jan;20(1):113-21. doi: 10.5056/jnm.2014.20.1.113. Epub 2013 Dec 30. PubMed PMID: 24466452; PubMed Central PMCID: PMC3895597.

4: Arigoni R, Chistè R, Makovec F, Setnikar I, Benfenati E, Fanelli R. Identification of metabolites of tiropramide in human urine. Biomed Environ Mass Spectrom. 1988 Feb 15;15(4):205-9. PubMed PMID: 3370360.

5: Setnikar I, Makovec F, Chistè R, Giachetti C, Zanolo G. Tiropramide and metabolites in blood and plasma after intravenous or peroral administration of 14C-tiropramide to the rat. Arzneimittelforschung. 1988 Dec;38(12):1815-9. PubMed PMID: 3245854.

6: Setnikar I, Makovec F, Chistè R, Giachetti C, Zanolo G. Distribution of tiropramide and metabolites after single intravenous or peroral administration of 14C-tiropramide to the rat. Arzneimittelforschung. 1989 May;39(5):579-86. PubMed PMID: 2757674.

7: Ryoo JJ, Heo KS, Choi ES, Park JH, Lee W. Enantioseparation of tiropramide by HPLC. Chirality. 2004;16 Suppl:S51-4. PubMed PMID: 15239073.

8: Kim SE, Zheng R, Kang D, Kim BH. Compartmental approach to assess bioequivalence compared to the noncompartmental approach. Int J Clin Pharmacol Ther. 2016 Jun;54(6):442-9. doi: 10.5414/CP202525. PubMed PMID: 27087152.

9: Takayanagi I, Hisayama T, Iwase M, Sakuma N, Nagai H. Pharmacological properties of tiropramide, an antispasmodic drug. Gen Pharmacol. 1989;20(3):335-9. PubMed PMID: 2744399.

10: Kwon OS, Park YJ, Chung YB. Pharmacokinetics and bioequivalence of tiropramide in healthy volunteers. Arzneimittelforschung. 2003;53(8):578-83. PubMed PMID: 13677248.

11: Setnikar I, Cereda R, Pacini MA, Revel L, Makovec F. Pharmacological characterisation of the smooth muscle antispasmodic agent tiropramide. Arzneimittelforschung. 1989 Sep;39(9):1114-9. PubMed PMID: 2590261.

12: Galeone M, Stock F, Moise G, Cacioli D, Benazzi E, Riva A. [Clinical and instrumental evaluation by multiple colonic manometry of tiropramide, trimebutine and octylonium bromide in the irritable colon: I. Administration by single i.v]. Pharmatherapeutica. 1986;4(7):445-56. Italian. PubMed PMID: 3960945.

13: Suda T, Onoe H, Takahira H. [Effect of tiropramide on the urination reflex]. Nihon Heikatsukin Gakkai Zasshi. 1989 Dec;25(6):248-50. Japanese. PubMed PMID: 2702256.

14: Morita T, Kondo T, Dokita S, Hirano S. [Tiropramide action on smooth muscle of the lower urinary tract]. Nihon Heikatsukin Gakkai Zasshi. 1989 Dec;25(6):243-5. Japanese. PubMed PMID: 2562023.

15: De Masi E. [Tiropramide hydrochloride in the premedication of diagnostic and therapeutic proctosigmoidocolonoscopy (endoscopic polypectomy) and the treatment of colonic diverticulosis]. Minerva Med. 1989 Jun;80(6):587-90. Italian. PubMed PMID: 2747989.

16: Trabucchi E, Baratti C, Centemero A, Zuin M, Rizzitelli E, Colombo R. Controlled study of the effects of tiropramide on biliary dyskinesia. Pharmatherapeutica. 1986;4(9):541-50. PubMed PMID: 2429334.

17: Arigoni R, Chisté R, Drovanti A, Makovec F, Senin P, Setnikar I. Pharmacokinetics of tiropramide after single doses in man. Arzneimittelforschung. 1986 Apr;36(4):738-44. PubMed PMID: 3718598.

18: Suda S, Takahira H, Onoe K, Tamura K. [Effects of tiropramide on the activity of lower urinary tract in dogs and its interpretation]. J Smooth Muscle Res. 1992 Feb;28(1):1-13. Japanese. PubMed PMID: 1392127.

19: Galeone M, Benazzi E, Bossi M, Moise G, Riva A, Stock F. [Clinical and instrumental evaluation by multiple colonic manometry of tiropramide, trimebutine and octylonium bromide in irritable colon. II. Repeated oral administration]. Pharmatherapeutica. 1986;4(8):496-509. Italian. PubMed PMID: 3714757.

20: Imran K, Punnamchand L, Natvarlal SM. A simple sample preparation with HPLC-UV method for estimation of tiropramide from plasma: application to bioequivalence study. J Pharm Biomed Anal. 2007 Feb 19;43(3):1135-40. Epub 2006 Nov 28. PubMed PMID: 17127027.